Stanford University
Showing 1,301-1,350 of 1,817 Results
-
Dyneisha Gray
Hit Program Administrator, Office of Technology Licensing (OTL)
Staff, Stanford Office of Technology LicensingBioDyneisha holds a B.S. in Business Administration from California State University Bakersfield. Dyneisha brings administrative experience from her previous roles as an Executive Assistant and Operations Manager for Viva Superheroes where she coordinated company events and managed calendars.
-
Jordan Gray
Director, Campus Engagement, Office of Community Engagement
Current Role at StanfordJordan is the Director of Campus Engagement and joined the Office of Community Engagement (OCE) in 2022 after Stanford Campus Engagement, where he previously served as the campus engagement program manager, merged with OCE to join External Relations.
As Director of Campus Engagement, Jordan leads efforts and works in collaboration with campus partners on projects, programs, and initiatives that promote and foster among the campus community (primarily staff, students, faculty, and post-docs) a sense and practice of connection to the mission of the university, the purpose of its activities, and the people who make up its community. -
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Robert M Gray
Alcatel-Lucent Professor in Communications and Networking, Emeritus
Current Research and Scholarly InterestsMy current research falls in the intersection of Shannon information theory and signal processing. In particular, I am interested in the theory and design of block codes and sliding-block (or stationary or time-invariant) codes for data compression and their relation to each other. Block codes are far better understood and more widely used, but their lack of stationarity causes difficulties in theory and artifacts in practice. Very little is known about the design of good sliding-block codes, but the problem is known to be equivalent to the design of entropy-constrained simulators of complex random processes. I also do research in the history of information theory and signal processing, especially in the development of speech processing systems and real time signal processing.
-
Carlos Greaves
Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences
BioBorn and raised in Caracas, Venezuela. Medical school at the Central University School of Medicine, where Internship was completed.
Residency training at Stanford Medical School, Department of Psychiatry. Work in Community Mental health in Maui, Hawaii for 4 years.
Work at the Veterans Administration in Palo Alto for 3 years. Currently in Private Practice and as consulting psychiatrist at the Vaden Student Health center at Stanford -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Brian Green
Physical Science Research Scientist
Current Research and Scholarly InterestsMy current research is on the dynamics and circulation of the stratosphere, focusing on quantifying the sources and effects of gravity waves. More broadly, I'm interested in and curious about a large range of topics relating to tropical climate, clouds, and the general circulation of the atmosphere and ocean.
-
Larry L. Green
Financial Analyst 3, Anesthesiology, Perioperative and Pain Medicine
Current Role at StanfordFinance Manager, Department of Anesthesia
-
Selina Zhao Green
Research Technical Manager, SLAC National Accelerator Laboratory
BioSelina joined SLAC National Accelerator Laboratory in 2005 after earning her Ph.D in Physics from University of Minnesota and conducting high-energy particle experiments at the Wilson Synchrontron Laboratory at Cornell University during the final 3 years of her graduate studies. At SLAC, she designed and constructed beamlines and diagnostics for the experimental area in Sector 20 of the SLAC Linac, as well as managing experiment installations.
In 2013, she served as a Project Manager for the 10-TW Ionization Laser project at the Facility for Advanced Accelerator Experimental Tests (FACET). She attained her Project Management Professional (PMP) Certification in 2016 when she became a Control Account Manager and was subsequently promoted to Project Manager for FACET-II, successfully leading the project team through its development from Conceptual Design, CD-1 to Final Design and construction CD-2/3.
Since September 2019, Selina had served as the Deputy Project Manager for the Matter in Extreme Conditions Upgrade (MEC-U) project, actively contributing to its planning and development.
In July 2025, Selina took on a new role within the Office of Project Management, where she continues to enhance project management practices and improve lab-wide procedures and programs. -
Seth Ariel Green
Data Aide 3, Pediatrics
Current Role at StanfordResearch Scientist at the Humane and Sustainable Food Lab
-
Sherril L. Green, DVM, PhD
Professor of Comparative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.
-
Tamar Green
Associate Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.
-
Yoel Green, MD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Sleep Medicine
BioDr. Yoel Green is a board-certified, fellowship-trained sleep medicine specialist at Stanford Health Care. He also serves as a clinical assistant professor in the Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine at Stanford University School of Medicine.
Dr. Green specializes in the diagnosis and treatment of sleep disorders, including narcolepsy, parasomnias, and obstructive sleep apnea (OSA). He also diagnoses and treats sleep-wake cycle disorders and restless legs syndrome (RLS). He integrates sleep data with patients’ lived experience to provide clear, personalized care.
Dr. Green’s research focuses on improving the diagnosis and treatment of sleep disorders. His work has appeared in peer-reviewed journals such as Biological Psychiatry and SLEEP. He has authored textbook chapters and presented at national meetings, including the American Psychiatric Association (APA) Annual Meeting.
Dr. Green is a member of the American Academy of Sleep Medicine, the APA, and the Canadian Sleep Society. -
Benjamin Daniel Greenberg
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioDr. Greenberg provides direct psychological care to patients in the ADAPT (Adult Depression and Anxiety Psychological Treatment) & Dual Diagnosis clinics. He is passionate about delivering evidence-based psychotherapies that are responsive and personal. He conducts individual as well as group therapy.
He teaches a psychotherapy didactic to the Addiction Medicine fellows as well as provides clinical supervision to post-doctoral fellows, doctoral students, and psychiatry residents. He is committed to helping trainees learn & work through complex situations that arise in individual & group psychotherapy. -
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
